Jason Zuckerbrod is a Partner at Centerview on the healthcare team. He has over 15 years of experience advising companies on mergers and acquisitions, shareholder activism, and other complex strategic issues. Select transactions Mr. Zuckerbrod has advised on include Express Scripts’s sale to Cigna for $67bn, Exact Science’s sale to Abbott for $23bn, Pfizer’s consumer healthcare joint venture with GSK, Tiffany & Co.’s sale to LVMH for $17bn, Intra-Cellular’s sale to J&J for $14.6bn, Pfizer’s acquisition of Medivation for $14bn, Biohaven’s sale to Pfizer for $12.5bn, Pfizer’s sale of its infant nutrition business to Nestle for $11.9bn, Acceleron’s sale to Merck for $11.5bn, Verona Pharma’s sale to Merck for $10bn, Ventas’s acquisition of Nationwide Health Properties for $7.4bn, Pfizer’s acquisition of Arena for $6.7bn, Pfizer’s acquisition of Anacor for $5.2bn, Amicus’s sale to BioMarin for $4.8bn, AtaiBeckley’s sale to Lilly for up to $3.9bn, Merck’s acquisition of Antelliq for €3.3bn, Chinook Therapeutics’s sale to Novartis for up to $3.5bn, Halda’s sale to J&J for $3.1bn, Soleno’s sale to Neurocrine for $2.9bn, Provention Bio’s sale to Sanofi for $2.9bn, Edgewise’s sale of Sevasemten to Servier for up to $2.65bn, DentaQuest’s sale to Sun Life for $2.5bn, Scorpion Therapeutics’s sale to Lilly for up to $2.5bn, Tanabe Pharma’s sale of Radicava to Shionogi for $2.5bn, Trillium’s sale to Pfizer for $2.3bn, Bellus Health’s sale to GSK for $2.0bn, KalVista’s sale to Chiesi for $1.9bn, Personalis’s sale to Tempus AI for $1.9bn, CinCor Pharma’s sale to AstraZeneca for up to $1.8bn, Perrigo’s sale of its generics business to Altaris for $1.6bn, Chiesi Farmaceutici’s acquisition of Amryt Pharma for up to $1.5bn, Transcend’s sale to Otsuka for up to $1.2bn, Albireo’s sale to Ipsen for up to $1.2bn, VectivBio’s sale to Ironwood for $1.2bn, Gracell Biotech’s sale to AstraZeneca for up to $1.2bn, Esperion’s sale to Archimed for up to $1.1bn, Inversago Pharma’s sale to Novo Nordisk for up to $1.075bn, FireFly’s sale to J&J for $1.0bn, Radius’s sale to B-Flexion, Ventas’s spin-off of Care Capital Properties, Anthem’s acquisition of America’s First Choice, Corium’s sale to Collegium for up to $785mm, Perrigo’s acquisition of Ranir for $750mm, Vigil Neuro’s sale to Sanofi for up to $593mm, ReViral’s sale to Pfizer for up to $525mm, Bausch Health’s acquisition of Durect for up to $413mm, MiroBio’s sale to Gilead for $405mm, Checkmate’s sale to Regeneron for $250mm, ProPharma Group’s sale to Odyssey, Thirty Madison’s acquisition of Nurx, Thirty Madison’s sale to Remedy Meds, and Express Scripts’s sale of UBC to Avista Capital. Mr. Zuckerbrod received a B.A., magna cum laude, from Columbia University and lives in Rye, NY with his wife, son, and daughter.